Combining chemerin receptor antagonists with standard chemotherapy could enhance the overall response rate by simultaneously targeting tumor cells and the tumor microenvironment, presenting an extremely promising and emerging therapeutic approach [60]. Here, CMKLR1 is linked to neoplasm.